Clinical Trial Update: Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial in advanced non-small cell lung cancer evaluating MaaT033 fecal microbiotherapy given with cemiplimab versus investigator's choice in pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Libtayo (cemiplimab)
• MaaT033

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Status: RECRUITING